Evotec SE Q3 2025 Earnings Recap

Evotec SE reported a 7% decline in year-to-date revenues to EUR 535.1 million, primarily due to ongoing challenges in the early drug discovery market, while its Just-Evotec Biologics division achieved robust growth of 11%.

Key Takeaways

• D&PD revenues fell by 12% to EUR 391.9 million, reflecting difficult market conditions amid reduced VC funding in biotech.
• Just-Evotec Biologics reported revenues of EUR 143.2 million, over 100% growth in non-Sandoz and non-DoD business, and a significant deal with Sandoz expected to generate over $650 million.
• Continued focus on cost management with a target of EUR 60 million in cost reductions, exceeding previous expectations, and an additional EUR 50 million in productivity measures planned.
• Momentum in strategic partnerships is strong, with up to 4 molecules anticipated to enter Phase II clinical studies in 2026, enhancing mid-term revenue prospects.
• Proposal activity has increased by 20% over the last two quarters, indicating stabilization in the D&PD business despite prevailing market challenges.